Immune-oncology firm Biotecnol and Cancer Research UK have entered a collaboration agreement to evaluate Tb535H in clinical trials to treat patients suffering from solid tumours.

Developed using the firm’s antibody development platform called Trisoma, Tb535H is an investigational immuno-oncology therapy designed to target the 5T4/WAIF1 tumour antigen protein that is believed to aid spread of the cancer.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Discovered by scientists at the Cancer Research UK Manchester Institute, the WAIF1 antigen is considered as an important target in various types of cancer.

Tb535H stimulates T-cells of the patient’s immune system to attack and fight against the tumours.

During the trial, the organisations intend to primarily focus on treatment of cancers that have a high unmet need. 

Cancer Research UK drug development director Dr Nigel Blackburn said: “It’s hugely exciting to be able to accelerate the development of a drug that could change outcomes for patients with many different types of cancer.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"It’s hugely exciting to be able to accelerate the development of a drug that could change outcomes for patients with many different types of cancer."

“Without this collaboration it might have been years before this treatment reached patients so we‘re pleased to work with Biotecnol to elevate their novel drug development platform.”

Cancer Research UK’s Centre for Drug Development will evaluate Tb535H in a Phase I clinical trial funded by Biotecnol, in return for the latter’s shareholdings.

Biotecnol CEO Pedro de Noronha Pissarra said: “The collaboration is important for Biotecnol’s strategy of working with top cancer institutions in the immune-oncology field, which will accelerate the development of cutting-edge therapeutic approaches to fight cancer.”

Initially, Tb535H will be assessed for non-small-cell lung cancer (NSCLC), renal cell carcinoma, and thoracic cancers such as mesothelioma and small-cell lung carcinoma (SCLC).

Cancer Research UK will support the early clinical development of the investigational candidate.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact